Auauniversity

Patrick Hamilton of CMS explains changes to the 2020 Merit-based Incentive Payment System (MIPS) and how this impacts reporting. Additionally, he answers questions from the audience highlighting issues important to urologic practices.

Dr. Eugene Rhee discusses getting your practice up and running with telemedicine on today's podcast. Dr. Rhee's comments include special considerations given the coronavirsus (COVID-19) pandemic's impact on healthcare delivery in the United States. Dr. Chris Gonzalez discusses considerations for elective urologic surgery given the coronavirsus (COVID-19) pandemic's impact on healthcare delivery in the United States. Dr. Gonzalez is chair of the AUA Public Policy Council. For more information, please visit the AUA's COVID-19 Information Center. https://www.auanet.org/covid-19-info-center

E.R. Mueller, MD, MSME - Loyola University Chicago Joseph C. Liao, MD - Stanford University J. Curtis Nickel, MD, FRCSC - Queen's University Daniel Shoskes, MD, FRCSC - Cleveland Clinic

This episode provides an introduction to the Urologic Diseases in America (UDA) Report and features perspectives from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Host: Brian Matlaga, MD, MPH, Johns Hopkins University School of Medicine Guest: Kevin Abbott, MD, MPH, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health This project has been funded in whole or in part with Federal funds from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N94019F00260.

Michel Pontari, MD Lewis Katz school of Medicine at Temple University AUA2019 Virtual Meeting available now: https://auau.auanet.org/content/aua2019-chicago-virtual-meeting-2019

CME Available: https://auau.auanet.org/node/27477 Course Director: Eric Rovner, MD Faculty: Kathleen Kobashi, MD Sandip Vasavada, MD At the conclusion of this activity, participants will be able to: 1. Define the similarities and differences between the various pharmacotherapies for OAB. 2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists and combination therapy. 3. Realize the importance of setting proper patient expectations regarding treatment of OAB and potential need for sequential and even additive therapies. 4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents. 5. Discuss potential future pharmacological pathways and therapies for OAB. This educational series is supported by an independent educational grant from: Astellas

Moderator John Brock, III, MD Professor and Director, Division of Pediatric Urology Debater - Pro(s) Richard Yu, MD,PHD Harvard Medical School Mohan Gundeti, MD The University of Chicago Debater - Con(s) Linda Baker, MD Professor of Urology The University of Texas Southwestern H. Rushton, Jr., MD Children's National Medical Center-The George Washington University Medical Center

Moderator(s) Jeremy Myers, MD University of Utah Debater - Pro(s) Hunter Wessells, MD, FACS Professor and Chair University of Washington School of Medicine Reynaldo Gomez, MD Hospital del Trabajador Debater - Con(s) Steven Brandes, MD Columbia University Medical Center Jill Buckley, MD, FACS University of California, San Diego

Moderator: Seth Cohen, MD Panelists: Gina Badalato, MD Kathleen Kieran, MD Kyle Zuniga (MS4) Vincent D'Andrea (MS4)

2019 AUA Annual Meeting Presidential Address Robert Flanigan, MD, FACS Loyola University Chicago Stritch School of Medicine

2018 AUA Annual Meeting Presidential Address J. Brantley Thrasher, MD, FACS Department of Urology, University of Kansas Health System

2017 AUA Annual Meeting Presidential Address Urology: A Personal Perspective Richard K. Babayan, MD, FACS

2016 AUA Annual Meeting Presidential Address William F. Gee, MD Lexington, KY

Co-Host: Jay Raman, MD, FACS At the conclusion of these activities, participants will be able to: 1. Review the mechanisms of action, efficacy, and safety of currently available targeted treatment of RCC. 2. Facilitate discussions with patients and caregivers regarding RCC treatment options. CME Available: auau.auanet.org/node/26091 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma

Co-Host: Yair Lotan, MD At the conclusion of these activities, participants will be able to: 1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients. 2. Facilitate discussions with patients and caregivers regarding of bladder cancer treatment options. CME Available: auau.auanet.org/node/26075 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma

Co-Host: Brian M. Shuch, MD At the conclusion of these activities, participants will be able to: 1. Describe a patient-specific treatment plan that optimizes the use of targeted and immunological agents for the treatment of kidney cancer. 2. Explain best practices in RCC patient selection for various treatment options CME Available: https://auau.auanet.org/node/26099 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma

Co-Host: Alexander Kutikov, MD, FACS At the conclusion of these activities, participants will be able to: 1. Discuss the evolving landscape of adjuvant therapy for the treatment of RCC. 2. Identify best practices for risk assessment and patient selection for adjuvant RCC therapy. 3. Differentiate the roles of urologist and medical oncologist in the care of patients with RCC. CME Available: auau.auanet.org/node/26087 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma

Co-Host: Alicia K. Morgans, MD, MPH At the conclusion of these activities, participants will be able to: 1. Recognize cardiovascular comorbidities and describe their management in the context of prostate cancer treatment. 2. Differentiate the roles of the urologist, other specialists and primary care providers in the care of patients with prostate cancer. CME Available: https://auau.auanet.org/node/26059 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma

Co-Host: Brian Shuch, MD At the conclusion of these activities, participants will be able to: 1. State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men. 2. Describe results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results. 3. Explain the importance of testing for germline mutations and their implication for novel therapies such as PARP inhibitors. CME Available: https://auau.auanet.org/node/26054 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma

Co-Host: Vitaly Margulis, MD At the conclusion of these activities, participants will be able to: 1. Identify new technologies for the treatment of urothelial carcinoma and analyze the risks and benefits of treatment. 2. Facilitate discussions with patients and caregivers regarding of urothelial carcinoma treatment options. CME Available: https://auau.auanet.org/node/26079 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma